Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis
Chalmers University of Technology spin out takes a different route to cancer biomarker identification
Executive Summary
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
You may also be interested in...
European Healthtech Grabs The Investor Headlines In H1 2022
After a runaway 2021 and a strong if bumpy first quarter of 2022, all health care product sectors underwent an investment dip in the second quarter, says Silicon Valley Bank. Healthtech in Europe remained a stand-out performer.
Positive Medtech Revenues Into H2, But M&A And IPOs May Wait
EY’s John Babitt provided a mid-year 2022 update on medtech investment trends, and the outlook for the industry going into 2023 in this commentary for In Vivo.
European Healthtech Grabs The Investor Headlines In H1 2022
After a runaway 2021 and a strong if bumpy Q1 2022, all health care product sectors underwent an investment dip in Q2, says Silicon Valley Bank. Healthtech in Europe remained a stand-out performer.